
Bobbi J Woolwine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/918815/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kynurenines increase MRS metabolites in basal ganglia and decrease resting-state connectivity in frontostriatal reward circuitry in depression. Translational Psychiatry, 2021, 11, 456.	4.8	8
2	Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming. Molecular Psychiatry, 2021, 26, 7384-7392.	7.9	15
3	543 - Cultural Considerations for Older LGBTQ Adults During the COVID-19 Pandemic: Case and Review. International Psychogeriatrics, 2021, 33, 85-86.	1.0	Ο
4	What does plasma CRP tell us about peripheral and central inflammation in depression?. Molecular Psychiatry, 2020, 25, 1301-1311.	7.9	251
5	Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression. Brain, Behavior, and Immunity, 2020, 88, 193-202.	4.1	21
6	Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology, 2020, 45, 998-1007.	5.4	101
7	Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. Brain, Behavior, and Immunity, 2020, 88, 161-165.	4.1	42
8	Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology, 2018, 98, 222-229.	2.7	44
9	Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Translational Psychiatry, 2018, 8, 189.	4.8	78
10	Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology, 2018, 95, 43-49.	2.7	186
11	Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. Brain, Behavior, and Immunity, 2018, 73, 725-730.	4.1	81
12	Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain, Behavior, and Immunity, 2016, 56, 281-288.	4.1	102
13	Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiology and Behavior, 2016, 166, 14-21.	2.1	38
14	Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. Brain, Behavior, and Immunity, 2015, 46, 17-22.	4.1	56
15	Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain, Behavior, and Immunity, 2015, 47, 193-200.	4.1	59
16	IFN-Alpha-Induced Cortical and Subcortical Glutamate Changes Assessed by Magnetic Resonance Spectroscopy. Neuropsychopharmacology, 2014, 39, 1777-1785.	5.4	130
17	Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. Brain, Behavior, and Immunity, 2013, 31, 153-160.	4.1	146
18	Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain, Behavior, and Immunity, 2013, 31, 205-215.	4.1	57

Bobbi J Woolwine

#	Article	IF	CITATIONS
19	A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression. JAMA Psychiatry, 2013, 70, 31.	11.0	1,314
20	Neurobehavioral Effects of Interferon-α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine. Neuropsychopharmacology, 2012, 37, 1444-1454.	5.4	51
21	Dopaminergic Mechanisms of Reduced Basal Ganglia Responses to Hedonic Reward During Interferon Alfa Administration. Archives of General Psychiatry, 2012, 69, 1044.	12.3	306
22	Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychological Medicine, 2012, 42, 1591-1603.	4.5	53
23	Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain, Behavior, and Immunity, 2011, 25, 1094-1098.	4.1	38
24	Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Molecular Psychiatry, 2010, 15, 535-547.	7.9	164
25	CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Molecular Psychiatry, 2010, 15, 393-403.	7.9	546
26	Chronic Interferon-Alpha Administration Disrupts Sleep Continuity and Depth in Patients with Hepatitis C: Association with Fatigue, Motor Slowing, and Increased Evening Cortisol. Biological Psychiatry, 2010, 68, 942-949.	1.3	106
27	Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression. Biological Psychiatry, 2009, 65, 296-303.	1.3	315
28	Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy. Neuropsychopharmacology, 2007, 32, 2384-2392.	5.4	203
29	Paroxetine for prevention of depressive symptoms induced by interferonâ€alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics, 2007, 25, 1163-1174.	3.7	130
30	Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study. Journal of Psychiatric Research, 2006, 40, 669-676.	3.1	29
31	Promoter Polymorphisms of the Interferon-α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings. Neuropsychobiology, 2005, 52, 55-61.	1.9	32
32	Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C. Brain, Behavior, and Immunity, 2005, 19, 23-27.	4.1	137
33	Anterior Cingulate Activation and Error Processing During Interferon-Alpha Treatment. Biological Psychiatry, 2005, 58, 190-196.	1.3	204
34	Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy. Journal of Clinical Psychiatry, 2005, 66, 41-48.	2.2	262
35	Relationship of Clinical Symptoms and Substance Use in Schizophrenia Patients on Conventional Versus Atypical Antipsychotics. American Journal of Drug and Alcohol Abuse, 2003, 29, 553-566.	2.1	29
36	Increased Early Life Stress and Depressive Symptoms in Patients With Comorbid Substance Abuse and Schizophrenia Bulletin, 2002, 28, 223-231.	4.3	48

#	Article	IF	CITATIONS
37	Double Jeopardy: Schizophrenia and Substance Use. American Journal of Drug and Alcohol Abuse, 2000, 26, 343-353.	2.1	73